GLP-1 (Glucagon-Like Peptide-1): Research Overview

GLP-1 is a hormone made by the small intestine. It helps trigger insulin release, which lowers blood sugar. In medicine, GLP-1 agonists are drugs that act like this hormone. They are used most often for type 2 diabetes, and some are also used for obesity. Researchers are still learning about their full range of effects and uses.

Key takeaways

• GLP-1 is a natural hormone with a central role in blood sugar control.
• GLP-1 agonists are usually injectable drugs, and they are used mainly for type 2 diabetes and sometimes obesity.
• Recent research highlighted large benefits in heart disease risk, including a 20% reduction in major heart events in a trial of more than 17,000 people without diabetes.
• Safety and quality matter. The FDA warns that unapproved GLP-1 products are risky, and that refrigeration during shipping is important for injectable drugs.

What GLP-1 is

GLP-1 stands for glucagon-like peptide-1. It is a hormone made in the small intestine. One of its main jobs is to help the pancreas release insulin. That matters because insulin helps the body use glucose for energy and lowers blood sugar. When insulin is not enough, blood sugar rises, which can lead to diabetes.

GLP-1 agonists are medicines designed to work like the natural hormone. Cleveland Clinic describes them as a class of medications that mainly help manage blood sugar in people with type 2 diabetes. Some of these medicines can also help treat obesity. They are usually given by injection under the skin, often in the belly, outer thighs, upper buttocks, or the backs of the arms.

The class has several other names in clinical use, including GLP-1 receptor agonists, incretin mimetics, and GLP-1 analogs. These drugs are relatively new. The first FDA-approved GLP-1 agonist, exenatide, was approved in 2005.

How GLP-1 agonists are used

GLP-1 agonists are not a stand-alone answer for type 2 diabetes or obesity. Cleveland Clinic notes that both conditions also require lifestyle and dietary changes. The medicine is one part of a broader treatment plan.

Recent discussion around GLP-1 has also expanded beyond glucose control. A public seminar described a wider cardiometabolic field that is changing quickly, with better outcomes, fewer side effects, easier adherence, and delivery options that are moving from injectables toward pills. That same discussion also noted development of dual agonists and triple agonists. In that setting, tirzepatide was described as part of the broader change in the class landscape, even though the core GLP-1 story still centers on blood sugar and weight management.

For people who reach a goal weight, one recent article noted that a GLP-1 maintenance dose may be recommended after reaching that goal. The stated purpose is to help prevent weight regain and support healthy maintenance.

What recent research is showing

Weight loss is the headline, but not the whole story

Semaglutide has been widely discussed because of weight loss results. One video source summarized clinical trial results as an average body weight reduction of around 15%. That number helps explain why these drugs drew so much attention. But the same source also argued that weight loss may not be the only important effect.

That matters because GLP-1 research is now tied to more than body weight. The best-known example in the bundle is the SELECT trial. It enrolled more than 17,000 people with heart disease who were overweight or obese, but who did not have diabetes. Half received semaglutide and half received placebo. The result reported in the source was a 20% reduction in the risk of heart attack, stroke, or death from a heart-related event.

That same source also said the heart protection appeared early in the trial, too early to be explained only by weight loss. That is an important point because it suggests GLP-1 drugs may affect more than body mass alone. The observation is presented here as a research interpretation, not as a settled mechanism.

Heart outcomes are part of the story now

The SELECT data are especially notable because the people in the trial did not have diabetes. That means the heart benefit was not limited to a diabetes population. For researchers and clinicians, that widens the practical question from “Does this help with weight?” to “What else might this class do for cardiometabolic risk?”

Another discussion in the bundle framed GLP-1 medicines as part of a larger wave of innovation in cardiometabolic health. It pointed to changes in indications, delivery systems, and combinations. That broader picture helps explain why GLP-1 research is moving quickly and why new questions keep appearing.

Muscle loss is a real concern

Not all of the discussion around GLP-1 drugs is positive. One source from Nutrishop states that up to 25–40% of weight loss may come from muscle. That figure is used there to argue for a more careful nutritional strategy.

The same source says appetite can drop enough to make it hard to eat enough protein. It recommends focusing on protein intake, exercise, and supplements to help preserve muscle. It also gives a target of 0.7 to 1 gram of protein per pound of body weight daily. Whether or not a person follows that exact target, the key research point is simple: weight loss is not only about fat loss, and lean mass deserves attention.

This is one reason GLP-1 research is not just about how much weight comes off. It is also about what kind of weight is lost, how to support body composition, and how to reduce unwanted trade-offs.

Safety, quality, and regulation

The FDA has issued clear warnings about unapproved GLP-1 drugs used for weight loss. According to the agency, unapproved versions do not undergo FDA review for safety, effectiveness, or quality before they are marketed. The FDA says compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug.

The agency also warns that injectable GLP-1 drugs require refrigeration as described in their package inserts. FDA has received complaints that some compounded GLP-1 products arrived warm or with too little ice to keep them at the right temperature. The agency recommends not using injectable GLP-1 drugs that arrive warm or without sufficient refrigeration, since quality can be affected.

This safety issue is not a side note. For researchers, clinicians, and patients, product quality is part of the evidence base. A drug can only be evaluated properly when the product is what it claims to be, stored correctly, and used under the conditions studied.

Why the quality issue matters

GLP-1 medicines are widely discussed, and the market has grown quickly. That growth can create pressure for lower-cost or easier-to-access alternatives. The FDA guidance is a reminder that access and quality are not the same thing. A product sold for weight loss is not automatically equivalent to an FDA-approved medicine. In research terms, that distinction matters because it affects both safety and interpretability.

What to watch in GLP-1 research

Several themes show up across the sources in this bundle. First, GLP-1 agonists are not just diabetes drugs anymore. They are now part of broader obesity and cardiometabolic care. Second, the field is moving beyond injectable use, with pills and combination approaches becoming part of the conversation. Third, researchers are still working out how much of the benefit comes from weight loss itself and how much comes from other effects.

There is also a clear practical question about maintenance. A lower maintenance dose after reaching a goal weight was described as a way to help prevent regain. That is important because long-term treatment is often different from initial weight loss treatment. The research conversation is shifting from “How do you start?” to “How do you maintain?”

Finally, the muscle-loss issue will likely stay central. If a medication changes appetite and body weight, it can also change protein intake, training capacity, and lean mass. That means future research will likely keep looking at nutrition, resistance exercise, and body composition, not just scale weight.

How to read the evidence

GLP-1 research is moving fast, but the best-supported claims in the bundle are still fairly specific. GLP-1 is a hormone involved in insulin release. GLP-1 agonists help manage blood sugar, and some help treat obesity. Semaglutide showed a 20% reduction in major heart events in a large trial of people with heart disease who did not have diabetes. FDA-approved products and compounded products are not the same thing. And weight loss with GLP-1 drugs may involve loss of muscle as well as fat.

That is enough to justify interest, but not enough to overstate certainty. The strongest reading of the current research is that GLP-1 is no longer just a glucose hormone. It is a central part of a broader cardiometabolic treatment class, with real benefits, real trade-offs, and active questions around long-term use.

FAQ

What does GLP-1 do in the body?

GLP-1 is a hormone made by the small intestine. One of its main roles is to trigger insulin release from the pancreas, which helps lower blood sugar.

What are GLP-1 agonists used for?

They are mainly used to help manage blood sugar in type 2 diabetes. Some are also used to treat obesity.

Are GLP-1 agonists usually injections?

Yes. Cleveland Clinic says they are most often injectable medicines given under the skin in places like the belly, thighs, buttocks, or arms.

What did the SELECT trial show?

The source in this bundle says semaglutide reduced the risk of heart attack, stroke, or death from a heart-related event by 20% in more than 17,000 people with heart disease who were overweight or obese and did not have diabetes.

Why is the FDA warning about compounded GLP-1 products?

The FDA says unapproved versions do not undergo agency review for safety, effectiveness, or quality before being marketed. It also warns that improper shipping and storage can affect the quality of injectable GLP-1 drugs.

Can GLP-1-related weight loss affect muscle?

Yes. One source in the bundle says up to 25–40% of weight loss may come from muscle, which is why protein intake, exercise, and muscle-preserving strategies are being discussed alongside GLP-1 use.